The FDA's Peripheral and Central Nervous System Drugs Advisory Committee voted 9 yes - 0 no, indicating sufficient evidence showing a reduction in plasma neurofilament light chain...
Biogen (BIIB) ALS Drug Receives Backing of FDA Panel in 9-0 Vote, FDA Says Tofersen Likely to Predict Benefit
By Davit Kirakosyan FDA posted documents yesterday ahead of the advisory panel for Biogen's (NASDAQ:BIIB) Tofersen for ALS. Needham believes these documents strike a favorable tone...
Looking for longs after a clear resumption of the uptrend.
CAMBRIDGE, Mass., March 16, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced that the Court of Justice of the European Union decided in favor of Biogen, the...
CAMBRIDGE, Mass., March 14, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (NASDAQ: BIIB) today announced the appointment of Chuck Triano as Senior Vice President, Head of Investor Relations...
Biogen Inc. is a global biopharmaceutical company. It is focused on discovering, developing and delivering therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies. It has a portfolio of medicines to treat multiple sclerosis (MS), spinal muscular atrophy (SMA) and Alzheimer's disease. Its marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; ADUHELM for the treatment of Alzheimer's disease; and FUMADERM for the treatment of severe plaque psoriasis. It also has a collaboration agreement with Genentech, Inc. (Genentech), a member of the Roche Group, with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions; RITUXAN HYCELA for the treatment of non-Hodgkin's lymphoma and CLL; GAZYVA; OCREVUS; and other potential anti-CD20 therapies, including mosunetuzumab.
| Average | 321.96 (+19.25% Upside) |
| High | 388.00 |
| Low | 249.00 |
| Price | 269.98 |
| No. of Analysts | 26 |
Type | Daily | Weekly | Monthly |
|---|---|---|---|
| Moving Averages | |||
| Technical Indicators | |||
| Summary |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 0.14 | 0.16 | 0.14 | -0.03 | -15.15% | 177.50K | Sydney | |||
| 4.785 | 4.83 | 4.77 | -0.035 | -0.73% | 423.71K | Sydney | |||
| 0.205 | 0.215 | 0.198 | +0.020 | +10.81% | 49.69M | Sydney | |||
| 64.30 | 64.49 | 63.25 | +0.72 | +1.13% | 101.51K | Sydney | |||
| 0.142 | 0.143 | 0.14 | +0.003 | +1.79% | 564.12K | Sydney | |||
| 13.35 | 13.50 | 13.20 | +0.05 | +0.38% | 124.00K | Sydney | |||
| 0.073 | 0.075 | 0.066 | +0.003 | +4.29% | 1.02M | Sydney | |||
| 0.061 | 0.061 | 0.061 | 0.00 | 0.00% | 0.00 | Sydney | |||
| 0.873 | 0.885 | 0.86 | -0.003 | -0.29% | 1.23M | Sydney | |||
| 0.024 | 0.024 | 0.022 | 0.00 | 0.00% | 0.00 | Sydney | |||
| 0.009 | 0.009 | 0.009 | 0.00 | 0.00% | 86.50K | Sydney | |||
| 2.69 | 2.71 | 2.69 | 0.00 | 0.00% | 0.00 | Sydney | |||
| 0.001 | 0.001 | 0.001 | 0.00 | 0.00% | 0.00 | Sydney | |||
| 0.011 | 0.011 | 0.01 | +0.001 | +5.00% | 4.21M | Sydney | |||
| 3.60 | 3.62 | 3.56 | +0.05 | +1.41% | 160.76K | Sydney |